Literature DB >> 26355153

Fstl1 Promotes Asthmatic Airway Remodeling by Inducing Oncostatin M.

Marina Miller1, Andrew Beppu1, Peter Rosenthal1, Alexa Pham1, Sudipta Das1, Maya Karta1, Dae Jin Song2, Christine Vuong1, Taylor Doherty1, Michael Croft3, Bruce Zuraw1, Xu Zhang4, Xiang Gao5, Seema Aceves6, Fazila Chouiali7, Qutayba Hamid7, David H Broide8.   

Abstract

Chronic asthma is associated with airway remodeling and decline in lung function. In this article, we show that follistatin-like 1 (Fstl1), a mediator not previously associated with asthma, is highly expressed by macrophages in the lungs of humans with severe asthma. Chronic allergen-challenged Lys-Cre(tg) /Fstl1(Δ/Δ) mice in whom Fstl1 is inactivated in macrophages/myeloid cells had significantly reduced airway remodeling and reduced levels of oncostatin M (OSM), a cytokine previously not known to be regulated by Fstl1. The importance of the Fstl1 induction of OSM to airway remodeling was demonstrated in murine studies in which administration of Fstl1 induced airway remodeling and increased OSM, whereas administration of an anti-OSM Ab blocked the effect of Fstl1 on inducing airway remodeling, eosinophilic airway inflammation, and airway hyperresponsiveness, all cardinal features of asthma. Overall, these studies demonstrate that the Fstl1/OSM pathway may be a novel pathway to inhibit airway remodeling in severe human asthma.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26355153      PMCID: PMC4811198          DOI: 10.4049/jimmunol.1501105

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  Follistatin-like-1, a diffusible mesenchymal factor determines the fate of epithelium.

Authors:  Tomohiro Umezu; Hiromi Yamanouchi; Yusuke Iida; Masataka Miura; Yasuhiro Tomooka
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-22       Impact factor: 11.205

Review 2.  Asthma phenotypes: the evolution from clinical to molecular approaches.

Authors:  Sally E Wenzel
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

Review 3.  Pathobiology of severe asthma.

Authors:  Humberto E Trejo Bittar; Samuel A Yousem; Sally E Wenzel
Journal:  Annu Rev Pathol       Date:  2014-11-24       Impact factor: 23.472

4.  Follistatin-like 1 suppresses sensory afferent transmission by activating Na+,K+-ATPase.

Authors:  Kai-Cheng Li; Fang-Xiong Zhang; Chang-Lin Li; Feng Wang; Ming-Yan Yu; Yan-Qing Zhong; Kai-Hua Zhang; Ying-Jin Lu; Qiong Wang; Xiao-Li Ma; Jun-Ru Yao; Jin-Yuan Wang; Li-Bo Lin; Mei Han; Yu-Qiu Zhang; Rohini Kuner; Hua-Sheng Xiao; Lan Bao; Xiang Gao; Xu Zhang
Journal:  Neuron       Date:  2011-03-10       Impact factor: 17.173

5.  Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma.

Authors:  Jasmina I Ivanova; Rachel Bergman; Howard G Birnbaum; Gene L Colice; Robert A Silverman; Kimmie McLaurin
Journal:  J Allergy Clin Immunol       Date:  2012-02-11       Impact factor: 10.793

6.  Chronic allergen challenge induces bronchial mast cell accumulation in BALB/c but not C57BL/6 mice and is independent of IL-9.

Authors:  Suzan Pae; Jae Youn Cho; Shanna Dayan; Marina Miller; Alan D Pemberton; David H Broide
Journal:  Immunogenetics       Date:  2010-05-18       Impact factor: 2.846

7.  Oncostatin-M up-regulates VCAM-1 and synergizes with IL-4 in eotaxin expression: involvement of STAT6.

Authors:  Dominik K Fritz; Christine Kerr; Li Tong; David Smyth; Carl D Richards
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

8.  Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart.

Authors:  Yuichi Oshima; Noriyuki Ouchi; Kaori Sato; Yasuhiro Izumiya; David R Pimentel; Kenneth Walsh
Journal:  Circulation       Date:  2008-06-02       Impact factor: 29.690

9.  Oncostatin M (OSM) is increased in asthma with incompletely reversible airflow obstruction.

Authors:  Jodie L Simpson; Katherine J Baines; Michael J Boyle; Rodney J Scott; Peter G Gibson
Journal:  Exp Lung Res       Date:  2009-11       Impact factor: 2.459

10.  ORMDL3 transgenic mice have increased airway remodeling and airway responsiveness characteristic of asthma.

Authors:  Marina Miller; Peter Rosenthal; Andrew Beppu; James L Mueller; Hal M Hoffman; Arvin B Tam; Taylor A Doherty; Matthew D McGeough; Carla A Pena; Maho Suzukawa; Maho Niwa; David H Broide
Journal:  J Immunol       Date:  2014-03-12       Impact factor: 5.422

View more
  19 in total

Review 1.  The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease.

Authors:  Kathryn L Pothoven; Robert P Schleimer
Journal:  Tissue Barriers       Date:  2017-06-13

2.  Cutting Edge: Targeting Epithelial ORMDL3 Increases, Rather than Reduces, Airway Responsiveness and Is Associated with Increased Sphingosine-1-Phosphate.

Authors:  Marina Miller; Arvin B Tam; James L Mueller; Peter Rosenthal; Andrew Beppu; Ruth Gordillo; Matthew D McGeough; Christine Vuong; Taylor A Doherty; Hal M Hoffman; Maho Niwa; David H Broide
Journal:  J Immunol       Date:  2017-03-08       Impact factor: 5.422

3.  Regulation of Pulmonary Bacterial Immunity by Follistatin-Like Protein 1.

Authors:  Matthew Henkel; Justin A Dutta; Jessica Partyka; Taylor Eddens; Raphael Hirsch; Jay K Kolls; Brian T Campfield
Journal:  Infect Immun       Date:  2020-12-15       Impact factor: 3.441

4.  GSDMB induces an asthma phenotype characterized by increased airway responsiveness and remodeling without lung inflammation.

Authors:  Sudipta Das; Marina Miller; Andrew K Beppu; James Mueller; Matthew D McGeough; Christine Vuong; Maya R Karta; Peter Rosenthal; Fazila Chouiali; Taylor A Doherty; Richard C Kurten; Qutayba Hamid; Hal M Hoffman; David H Broide
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

5.  Blocking follistatin-like 1 attenuates liver fibrosis in mice by regulating transforming growth factor-beta signaling.

Authors:  Xiao-Hua Zhang; Yong Chen; Bin Li; Ji-Yong Liu; Chong-Mei Yang; Ming-Ze Ma
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

6.  Neutrophils are a major source of the epithelial barrier disrupting cytokine oncostatin M in patients with mucosal airways disease.

Authors:  Kathryn L Pothoven; James E Norton; Lydia A Suh; Roderick G Carter; Kathleen E Harris; Assel Biyasheva; Kevin Welch; Stephanie Shintani-Smith; David B Conley; Mark C Liu; Atsushi Kato; Pedro C Avila; Qutayba Hamid; Leslie C Grammer; Anju T Peters; Robert C Kern; Bruce K Tan; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2016-12-18       Impact factor: 10.793

Review 7.  The SPARC protein: an overview of its role in lung cancer and pulmonary fibrosis and its potential role in chronic airways disease.

Authors:  Sharon L I Wong; Maria B Sukkar
Journal:  Br J Pharmacol       Date:  2016-11-25       Impact factor: 8.739

8.  Orosomucoid-like 3 (ORMDL3) upregulates airway smooth muscle proliferation, contraction, and Ca2+ oscillations in asthma.

Authors:  Jun Chen; Marina Miller; Hirotoshi Unno; Peter Rosenthal; Michael J Sanderson; David H Broide
Journal:  J Allergy Clin Immunol       Date:  2017-09-07       Impact factor: 10.793

9.  FSTL-1 Attenuation Causes Spontaneous Smoke-Resistant Pulmonary Emphysema.

Authors:  Matthew Henkel; Jessica Partyka; Alyssa D Gregory; Erick Forno; Michael H Cho; Taylor Eddens; Andrew R Tout; Nathan Salamacha; William Horne; Krithika S Rao; Yijen Wu; John F Alcorn; Dennis Kostka; Raphael Hirsch; Juan C Celedón; Steven D Shapiro; Jay K Kolls; Brian T Campfield
Journal:  Am J Respir Crit Care Med       Date:  2020-04-15       Impact factor: 21.405

10.  Segmental allergen challenge increases levels of airway follistatin-like 1 in patients with asthma.

Authors:  Marina Miller; Stephane Esnault; Richard C Kurten; Elizabeth A Kelly; Andrew Beppu; Sudipta Das; Peter Rosenthal; Joe Ramsdell; Michael Croft; Bruce Zuraw; Nizar Jarjour; Qutayba Hamid; David H Broide
Journal:  J Allergy Clin Immunol       Date:  2016-04-20       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.